Bcl-2
Bax
Caspase-7
Caspase-8
PARP
Dehydrocorydaline (0-200 μM) treatment significantly inhibits the growth of MCF-7 cells in a dose-dependent manner. The cell viability is decreased by approximate 40% after 24 h of 200 μM Dehydrocorydaline. Dehydrocorydaline (0-200 μM)dose-dependently increases Bax protein expression and decreases Bcl-2 protein expression. Dehydrocorydaline (0-200 μM)induces activation of caspase-7,-8 and the cleavage of PARP without affecting caspase-9.
Dehydrocorydaline manifests a low acute toxicity with an LD 50 of about 277.5±19.0 mg/kg body weight in mice following oral administration and 21.1±1.4 mg/kg for intraperitoneal injection.